| Literature DB >> 35116585 |
Hao Song1,2, Ranran Yang3,4, Kailiu Wu1,2, Chao Lou1,2, Meng Xiao1,2, Wei Guo1,2, Guoxin Ren1,2.
Abstract
BACKGROUND: The purpose of the present study was to investigate the clinicopathological characteristics and prognostic factors of second primary oral squamous cell carcinoma after radiotherapy for head and neck cancer.Entities:
Keywords: Second primary; malignancy; oral cavity; radiation; squamous cell carcinoma
Year: 2021 PMID: 35116585 PMCID: PMC8797445 DOI: 10.21037/tcr-21-283
Source DB: PubMed Journal: Transl Cancer Res ISSN: 2218-676X Impact factor: 1.241
Figure 1OS and DFS of NPC survivors and non-NPC survivors. (A) OS of NPC survivors and non-NPC survivors showed no significant difference. (B) NPC survivors showed a trend of better DFS than non-NPC survivors, but the difference showed no significance (P=0.055). OS, overall survival; NPC, nasopharyngeal carcinoma; DFS, disease free survival.
Demographic and clinicopathological data of 48 patients with second primary OSCC
| Characteristic | No. of patients |
|---|---|
| Age | |
| ≥60 years | 25 |
| <60 years | 23 |
| Gender | |
| Male | 32 |
| Female | 16 |
| Drinker | |
| Yes | 7 |
| No | 41 |
| Smoker | |
| Yes | 12 |
| No | 36 |
| Tumor site | |
| Tongue | 18 |
| Gingiva | 10 |
| Buccal | 12 |
| Floor of mouth | 4 |
| Palate | 3 |
| Mandibular bone | 1 |
| Clinical stage | |
| I | 5 |
| II | 8 |
| III | 8 |
| IV | 27 |
| Tumor stage | |
| T1 | 6 |
| T2 | 10 |
| T3 | 6 |
| T4 | 26 |
| Status of lymph node | |
| N0 | 36 |
| N+ | 12 |
| Differentiation | |
| Well or moderate | 43 |
| Poor | 5 |
| Margin status | |
| Positive | 9 |
| Negative | 39 |
| Treatment mode | |
| Surgery only | 37 |
| Surgery + adjuvant therapy | 11 |
OSCC, oral squamous cell carcinoma.
Prognostic factors for the OS and DFS in patients with secondary OSCC
| Parameters | No. of case | 5-year OS (%) | Log-rank | Cox regression | 3-year DFS (%) | Log-rank | Cox regression | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | ||||||||||
| P | HR (95% CI) | P | HR (95% CI) | P | P | HR (95% CI) | P | |||||
| Age | 0.151 | 0.582 (0.274–1.234) | 0.151 | – | – | 0.934 | 0.972 (0.485–1.947) | 0.936 | ||||
| ≥60 years | 25 | 49.0 | 35.6 | |||||||||
| <60 years | 23 | 30.4 | 36.3 | |||||||||
| Gender | 0.519 | 0.783 (0.371–1.652) | 0.519 | – | – | 0.903 | 0.957 (0.467–1.961) | 0.905 | ||||
| Male | 32 | 45.8 | 39.3 | |||||||||
| Female | 16 | 27.3 | 30.0 | |||||||||
| Drinker | 0.378 | 1.886 (0.447–7.962) | 0.388 | – | – | 0.774 | 1.162 (0.407–3.314) | 0.779 | ||||
| Yes | 7 | 68.6 | 38.1 | |||||||||
| No | 41 | 36.4 | 35.3 | |||||||||
| Smoker | 0.149 | 2.138 (0.740–6.183) | 0.161 | – | – | 0.650 | 1.209 (0.523–2.798) | 0.657 | ||||
| Yes | 12 | 62.9 | 38.9 | |||||||||
| No | 36 | 32.9 | 34.6 | |||||||||
| Clinical stage | 0.494 | 1.345 (0.571–3.167) | 0.497 | – | – | 0.929 | 1.035 (0.478–2.238) | 0.931 | ||||
| I + II | 13 | 50.8 | 38.5 | |||||||||
| III + IV | 35 | 35.0 | 34.8 | |||||||||
| Margin status | 0.001 | 4.033 (1.643–9.899) | 0.002 | 3.976 (1.596–9.904) | 0.003 | 0.001 | 3.538 (1.608–7.782) | 0.002 | ||||
| Positive | 9 | 22.2 | 11.1 | |||||||||
| Negative | 39 | 44.9 | 41.5 | |||||||||
| Lymph node | 0.865 | 1.071 (0.483–2.377) | 0.866 | – | – | 0.514 | 1.277 (0.603–2.705) | 0.524 | ||||
| N+ | 14 | 39.7 | 22.2 | |||||||||
| N0 | 34 | 39.4 | 40.4 | |||||||||
| ENE | 0.050 | 2.765 (0.954–8.012) | 0.061 | 2.622 (0.891–7.721) | 0.080 | 0.410 | 1.626 (0.491–5.387) | 0.426 | ||||
| + | 4 | 40.8 | 37.0 | |||||||||
| − | 44 | 25.0 | 25.0 | |||||||||
| Differentiation | 0.501 | 1.434 (0.497–4.141) | 0.505 | – | – | 0.814 | 0.869 (0.265–2.857) | 0.818 | ||||
| Poor | 5 | 40.0 | 40.0 | |||||||||
| Well & moderate | 43 | 39.4 | 35.2 | |||||||||
| Treatment mode | 0.907 | 0.948 (0.383–2.345) | 0.908 | – | – | 0.878 | 0.937 (0.405–2.170) | 0.880 | ||||
| Surgical only | 37 | 39.3 | 39.3 | |||||||||
| Comprehensive | 11 | 40.0 | 40.0 | |||||||||
OS, overall survival; DFS, disease-free survival; HR, hazard ratio; ENE, extra-nodal extension.
Figure 2Prognostic factors of second OSCC. Kaplan-Meier analysis of 48 patients with second OSCC by margin status (A,C), ENE (B) and clinical stage (D). The log-rank test showed that patients with positive margin had a worse OS (A) and DFS (C), and patients with ENE+ had a worse OS (B). While clinical stage was not significantly associated with OS (D). OSCC, oral squamous cell carcinoma; ENE, extranodal extension; OS, overall survival; DFS, disease free survival.